InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Cover Story

  • Your step-by-step guide to IP lobbying

    As IP issues move up the political agenda IP owners and their lawyers have their biggest opportunity yet to influence the policy making process. Emma Barraclough and Eileen McDermott explain how to do it

  • A history of IP lobbying

    Managing IP profiles some of the most heavily lobbied IP issues worldwide and considers how IP owners and activists shaped the debate - and the outcome

  • Avoid a PR disaster in Asia

    IP lobbying extends to more than just official policy making. Peter Ollier looks at how companies can ensure that their voice is heard during litigation in Asia

Features

IP Clinic

  • How do we stop lookalikes?

    Our company launched a new product last year but we have since discovered that a leading supermarket is selling an own brand version that looks very similar. What should we do?

Diary

  • Utynam's Heirs

    A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world's first recorded patent in 1449

Country Updates

profile

Managing IP

ManagingIP

ManagingIP profile

Graphics showing what patent protection will cost in Europe, post- #unitarypatent ($/trial) http://t.co/EClJx919gW http://t.co/GBc0XfX2yz

Jul 3 2015 02:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @The_IPO: Do you work in #mediarelations or know someone who does? @The_IPO have a vacancy in our #London office http://t.co/SkHPfN2yIY

Jul 3 2015 01:48 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @OAMITWEETS: Our webinar programme for July 7 http://t.co/CbPXRi0ITB

Jul 3 2015 11:45 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements